Kus, T. Et Al. 2016. Tyrosine kinase inhibitors improve parenchymal findings of liver cirrhosis in a patient exhibiting concomitant hepatocellular carcinoma and renal cell cancer. MOLECULAR AND CLINICAL ONCOLOGY , vol.4, no.2 , 290-292.

Kus, T., Aktas, G., Sevinc, A., Oktay, C., KALENDER, M. E., & CAMCI, C., (2016). Tyrosine kinase inhibitors improve parenchymal findings of liver cirrhosis in a patient exhibiting concomitant hepatocellular carcinoma and renal cell cancer. MOLECULAR AND CLINICAL ONCOLOGY , vol.4, no.2, 290-292.

Kus, Tulay Et Al. "Tyrosine kinase inhibitors improve parenchymal findings of liver cirrhosis in a patient exhibiting concomitant hepatocellular carcinoma and renal cell cancer," MOLECULAR AND CLINICAL ONCOLOGY , vol.4, no.2, 290-292, 2016

Kus, Tulay Et Al. "Tyrosine kinase inhibitors improve parenchymal findings of liver cirrhosis in a patient exhibiting concomitant hepatocellular carcinoma and renal cell cancer." MOLECULAR AND CLINICAL ONCOLOGY , vol.4, no.2, pp.290-292, 2016

Kus, T. Et Al. (2016) . "Tyrosine kinase inhibitors improve parenchymal findings of liver cirrhosis in a patient exhibiting concomitant hepatocellular carcinoma and renal cell cancer." MOLECULAR AND CLINICAL ONCOLOGY , vol.4, no.2, pp.290-292.

@article{article, author={Tulay Kus Et Al. }, title={Tyrosine kinase inhibitors improve parenchymal findings of liver cirrhosis in a patient exhibiting concomitant hepatocellular carcinoma and renal cell cancer}, journal={MOLECULAR AND CLINICAL ONCOLOGY}, year=2016, pages={290-292} }